Cargando…
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
Oral bisphosphonates are of proven efficacy in preventing fractures in postmenopausal osteoporosis. However, poor adherence limits their real-world efficacy and clinical utility. Zoledronic acid (ZOL) is a potent bisphosphonate administered by annual intravenous infusion, effectively ensuring adhere...
Autores principales: | Carmona, Raj, Adachi, Rick |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778428/ https://www.ncbi.nlm.nih.gov/pubmed/19936161 |
Ejemplares similares
-
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008) -
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017) -
Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women
por: Chao, Ma, et al.
Publicado: (2013) -
Once-yearly zoledronic acid in hip fracture prevention
por: Demontiero, Oddom, et al.
Publicado: (2009) -
Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)